Tuesday, November 23, 2021

To the Office of Attorney General:

Pursuant to 18 V.S.A.§ 4637 (Notice of Introduction of New High-Cost Prescription Drugs), effective July1, 2018, when a prescription drug manufacturer introduces a new prescription drug to market at a wholesale acquisition price above the threshold set for a specialty drug under the Medicare Part D program, that manufacturer is required to provide certain written information to the Attorney General's Office.

Per section (2)(c) of § 4637 Notice Of Introduction Of New High-Cost Prescription Drugs, Novartis is notifying the Office of the Attorney General in the state of Vermont the Wholesaler Acquisition Cost (WAC) within 30 calendar days following the release of Scemblix into the commercial market.

Please see table below:

| NDC | Drug Product Description | Introduction to Market | WAC at Introduction |
|---|---|---|---|
| 00078-1091-20 | SCEMBLIX (asciminib) 20 mg, 60tablets | October 29, 2021 | $17,900.00 |
| 00078-1098-20 | SCEMBLIX (asciminib) 40 mg, 60tablets | October 29, 2021 | $17,900.00 |

| Estimated volume of patients who may be prescribed drug in 2021 | Breakthrough therapy designation? (Y/N) | Priority Review? (Y/N) | Date and price of acquisition if the drug was not developed by the manufacturer else N/A |
|---|---|---|---|
| 225 | Yes | Yes | N/A |
| 225 | Yes | Yes | N/A |

| A description of the marketing and pricing plans used in the launch of the new drug |
|---|
| The marketing for SCEMBLIX includes education and promotion to physicians, direct to consumer promotions, other types of marketing (e.g., online platforms and education). Novartis considered many factors in determining the price of SCEMBLIX. SCEMBLIX is the first FDA-approved CML treatment that works by binding to the ABL myristoyl pocket, and represents an important development for patients who experience resistance and/or intolerance to currently available TKI therapies1-3. We priced in parity to other branded treatments in this therapeutic area and are focused on access to SCEMBLIX i for this patient population. |
| The marketing for SCEMBLIX includes education and promotion to physicians, direct to consumer promotions, other types of marketing (e.g., online platforms and education). Novartis considered many factors in determining the price of SCEMBLIX. SCEMBLIX is the first FDA-approved CML treatment that works by binding to the ABL myristoyl pocket, and represents an important development for patients who experience resistance and/or intolerance to currently available TKI therapies1-3. We priced in parity to other branded treatments in this therapeutic area and are focused on access to SCEMBLIX i for this patient population. |